LEO Pharma, a leader in dermatology, has announced the publication of its DELTA 1 and DELTA 2 phase 3 trial findings for delgocitinib cream in The Lancet, a renowned peer-reviewed medical journal. This publication marks a significant advancement in understanding and treating chronic hand eczema (CHE).
The DELTA 1 and DELTA 2 trials evaluated the safety and effectiveness of delgocitinib cream against a cream vehicle in patients with moderate to severe CHE who had limited response to traditional treatments. The results, published in The Lancet, demonstrated that delgocitinib cream met its primary and secondary endpoints, indicating its potential as a promising new treatment option.
The findings of the DELTA trials highlight the growing research and awareness surrounding CHE. Dr. Robert Bissonnette, Lead Author and MD from Innovaderm Research, Montreal, emphasized the importance of these publications in bringing attention to the condition and facilitating further scientific advancements.
Delgocitinib cream is currently under investigation and is awaiting approval from health authorities. LEO Pharma believes its potential to alleviate the symptoms and improve the quality of life for patients with CHE is significant. The company is eager to share the research findings with the scientific community to inspire further research and drive progress in CHE management.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
